ES2097808T3 - Anticuerpos de marco conservado mutado y su preparacion. - Google Patents

Anticuerpos de marco conservado mutado y su preparacion.

Info

Publication number
ES2097808T3
ES2097808T3 ES91907669T ES91907669T ES2097808T3 ES 2097808 T3 ES2097808 T3 ES 2097808T3 ES 91907669 T ES91907669 T ES 91907669T ES 91907669 T ES91907669 T ES 91907669T ES 2097808 T3 ES2097808 T3 ES 2097808T3
Authority
ES
Spain
Prior art keywords
preserved
antibodies
preparation
derived
framework
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91907669T
Other languages
English (en)
Inventor
Wellcome Foundation Ltd The
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10682322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2097808(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Application granted granted Critical
Publication of ES2097808T3 publication Critical patent/ES2097808T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

SE PRODUCE UNA CADENA DE ANTICUERPOS ALTERADA EN QUE LOS CDRS DEL DOMINIO VARIABLE DE LA CADENA SE DERIVAN DE UNA PRIMERA ESPECIE DE MAMIFEROS. LAS REGIONES QUE CODIFICAN EL SOPORTE DE ADN QUE CODIFICA EL DOMINIO VARIABLE DE LA PRIMERA ESPECIE SE MUTAN DE TAL COMO DE LAS REGIONES QUE CODIFICAN EL SOPORTE MUTADAS CODIFICAN UN SOPORTE DERIVADO DE UNA SEGUNDA ESPECIE DE MAMIFEROS. EL DOMINIO O CADA UNO DE LOS DOMINIOS CONSTANTES DE LA CADENA DEL ANTICUERPO, SI SE ENCONTRARA PRESENTE, SE DERIVAN TAMBIEN DE LA SEGUNDA ESPECIE DE MAMIFEROS. TAMBIEN SE PRESENTA UN ANTICUERPO CAPAZ DE ENLAZARSE A UN ANTIGENO CD4 HUMANO JUNTO CON UNA COMPOSICION FARMACEUTICA QUE CONTIENE EL ANTICUERPO.
ES91907669T 1990-09-17 1991-09-16 Anticuerpos de marco conservado mutado y su preparacion. Expired - Lifetime ES2097808T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909020282A GB9020282D0 (en) 1990-09-17 1990-09-17 Altered antibodies and their preparation

Publications (1)

Publication Number Publication Date
ES2097808T3 true ES2097808T3 (es) 1997-04-16

Family

ID=10682322

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91907669T Expired - Lifetime ES2097808T3 (es) 1990-09-17 1991-09-16 Anticuerpos de marco conservado mutado y su preparacion.

Country Status (20)

Country Link
US (5) USRE46877E1 (es)
EP (1) EP0549581B2 (es)
JP (1) JPH06502762A (es)
KR (1) KR100217212B1 (es)
AT (1) ATE148172T1 (es)
AU (1) AU660151B2 (es)
CA (1) CA2091769C (es)
DE (1) DE69124387T3 (es)
DK (1) DK0549581T3 (es)
ES (1) ES2097808T3 (es)
GB (1) GB9020282D0 (es)
GR (1) GR3023252T3 (es)
ID (1) ID1044B (es)
IE (1) IE913257A1 (es)
IL (1) IL99499A (es)
MX (1) MX9101117A (es)
MY (1) MY111682A (es)
NZ (1) NZ239826A (es)
WO (1) WO1992005274A1 (es)
ZA (1) ZA917407B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
GB9206422D0 (en) * 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
CA2221350A1 (en) * 1995-05-18 1996-11-21 Ortho Pharmaceutical Corporation Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US6972324B2 (en) 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
AR036154A1 (es) * 2001-05-18 2004-08-18 Boehringer Ingelheim Pharma Anticuerpos especificos de cd44v6.
GB2376466A (en) * 2001-06-14 2002-12-18 Mark Frewin TRX1 antibody
US8165535B2 (en) * 2006-06-04 2012-04-24 Samsung Electro-Mechanics Systems, methods and apparatuses for complementary metal oxide semiconductor (CMOS) antenna switches using switched resonators
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
EP1585768A2 (en) * 2003-01-23 2005-10-19 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
US7700737B2 (en) 2003-12-05 2010-04-20 Multimmune Gmbh Therapeutic and diagnostic anti-Hsp70 antibodies
WO2006015373A2 (en) * 2004-08-04 2006-02-09 Amgen Inc Antibodies to dkk-1
WO2006126068A2 (en) * 2005-05-24 2006-11-30 Avestha Gengraine Technologies Pvt Ltd Recombinant method for the production of a monoclonal antibody to cd52 for the treatment of chronic lymphocytic leukemia
WO2008081008A1 (en) 2007-01-05 2008-07-10 University Of Zurich Method of providing disease-specific binding molecules and targets
EP2457928B1 (en) 2007-03-13 2017-05-10 Universität Zürich Monoclonal human tumor-specific antibody
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
EP2527369A3 (en) 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US9005963B2 (en) 2008-10-14 2015-04-14 Ablynx N.V. Amino acid sequences directed against cellular receptors for viruses and bacteria
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
ES2724975T3 (es) 2009-12-10 2019-09-18 Regeneron Pharma Ratones que producen anticuerpos de cadena pesada
DE202011103324U1 (de) 2011-07-12 2012-01-02 Nekonal S.A.R.L. Therapeutische anti-TIRC7 Antikörper für die Verwendung in Immun und anderen Krankheiten
ME03008B (me) 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
AU2012328819B2 (en) 2011-10-26 2017-08-03 Elanco Tiergesundheit Ag Monoclonal antibodies and methods of use
WO2013093122A2 (en) 2011-12-23 2013-06-27 Phenoquest Ag Antibodies for the treatment and diagnosis of affective and anxiety disorders
WO2013098420A1 (en) 2011-12-28 2013-07-04 Immunoqure Ag Method of isolating human antibodies
JP6742237B2 (ja) 2013-07-03 2020-08-19 イムノキュア アーゲーＩｍｍｕｎｏｑｕｒｅ Ａｇ ヒト抗ｉｆｎ−アルファ抗体
US8883157B1 (en) 2013-12-17 2014-11-11 Kymab Limited Targeting rare human PCSK9 variants for cholesterol treatment
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
US9139648B1 (en) 2014-07-15 2015-09-22 Kymab Limited Precision medicine by targeting human NAV1.9 variants for treatment of pain
WO2022153212A1 (en) 2021-01-13 2022-07-21 Axon Neuroscience Se Antibodies neutralizing sars-cov-2

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4652447A (en) 1979-04-26 1987-03-24 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human helper T cells
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US4695459A (en) 1984-12-26 1987-09-22 The Board Of Trustees Of Leland Stanford Junior University Method of treating autoimmune diseases that are mediated by Leu3/CD4 phenotype T cells
US4681760A (en) 1985-04-17 1987-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of conferring immunotolerance to a specific antigen
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
AU625613B2 (en) 1988-01-05 1992-07-16 Novartis Ag Novel chimeric antibodies
JP2646007B2 (ja) 1988-01-30 1997-08-25 財団法人 化学及血清療法研究所 抗ｈｉｖ抗体可変領域をコードする遺伝子断片およびこれらを用いて発現された抗ｈｉｖキメラ抗体ならびにその製法
JP3121823B2 (ja) 1988-02-12 2001-01-09 ビーティージー・インターナショナル・リミテッド 抗体におけるまたは抗体に関する改良
WO1989009622A1 (en) 1988-04-15 1989-10-19 Protein Design Labs, Inc. Il-2 receptor-specific chimeric antibodies
EP0365209A3 (en) 1988-10-17 1990-07-25 Becton, Dickinson and Company Anti-leu 3a amino acid sequence
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
ATE125305T1 (de) 1989-01-23 1995-08-15 Abbott Lab Monoklonale antikörper von ratten gegen menschliche antigene und verfahren zu deren herstellung.
CA2018248A1 (en) 1989-06-07 1990-12-07 Clyde W. Shearman Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
JPH0353894A (ja) 1989-07-21 1991-03-07 Calpis Food Ind Co Ltd:The 抗ヒトｃｄ４ペプチドに対するモノクローナル抗体
GB8925590D0 (en) 1989-11-13 1990-01-04 Central Blood Lab Authority Monoclonal antibodies
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9020282D0 (en) * 1990-09-17 1990-10-31 Gorman Scott D Altered antibodies and their preparation
GB9022543D0 (en) 1990-10-17 1990-11-28 Wellcome Found Antibody production
EP1400536A1 (en) * 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody

Also Published As

Publication number Publication date
DE69124387D1 (de) 1997-03-06
CA2091769C (en) 2002-07-23
EP0549581B2 (en) 2010-04-28
US20070212753A1 (en) 2007-09-13
USRE43898E1 (en) 2013-01-01
NZ239826A (en) 1992-12-23
MY111682A (en) 2000-11-30
JPH06502762A (ja) 1994-03-31
US7098006B1 (en) 2006-08-29
DE69124387T2 (de) 1997-05-15
IL99499A0 (en) 1992-08-18
AU660151B2 (en) 1995-06-15
IE913257A1 (en) 1992-02-25
USRE46877E1 (en) 2018-05-29
KR930702535A (ko) 1993-09-09
DK0549581T3 (da) 1997-05-26
WO1992005274A1 (en) 1992-04-02
GB9020282D0 (en) 1990-10-31
KR100217212B1 (ko) 1999-10-01
AU8508891A (en) 1992-04-15
CA2091769A1 (en) 1992-03-18
GR3023252T3 (en) 1997-07-30
IL99499A (en) 2006-08-20
DE69124387T3 (de) 2011-02-17
EP0549581B1 (en) 1997-01-22
MX9101117A (es) 1992-05-04
ATE148172T1 (de) 1997-02-15
EP0549581A1 (en) 1993-07-07
ZA917407B (en) 1992-06-24
US6767996B1 (en) 2004-07-27
ID1044B (id) 1996-10-28

Similar Documents

Publication Publication Date Title
ES2097808T3 (es) Anticuerpos de marco conservado mutado y su preparacion.
ATE95068T1 (de) Modifizierte antikoerper.
AU5055593A (en) Antibodies specific for HIV
DK0414475T3 (da) Fremgangsmåder til dyrkning af HCV i B- eller T-lymfocyt-cellelinier
BG101105A (bg) Заместени бензамидини, тяхното получаване и използването им като лекарствени средства
FI893428A7 (fi) TNF-a:n in vitro ja in vivo toksisten ominaisuuksien eliminointi monoklonaalisilla vasta-aineilla ja niistä johdetuilla fragmenteilla
DE3788148D1 (de) Monoklonale Antikörper und deren Verwendung.
ATE114713T1 (de) Biomasse zur produktion von virus/virusantigen.
GR3029483T3 (en) Antibodies against t-cells as therapeutics
ATE71149T1 (de) Monoklonale antikoerper.
JPS6461499A (en) Monoclonal antibody to human papilloma viruses 16 type e7 protein, and production and use thereof
IE792390L (en) Hepatitis be antigen.
CA2095735A1 (en) Monoclonal antibodies to hepatitis c virus and method for using same
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
DE69111429D1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
ATE148163T1 (de) Monoklonale antikörper gegen leptosphaeria
DE59301478D1 (de) Nachweis von viralen oder bakteriellen Antigenen mittels Durchflusscytometrie
ATE148162T1 (de) Monoklonale antikörper gegen mycosphaerella-arten
IT8821547A0 (it) Metodo immunologico per la determinazione di anticorpi anti antigeni di microorganismi, mediante anticorpi antiidiotipo e mezzi adatti allo scopo.
BG48881A1 (en) Hybridomic cell line mus musculus h 5/9, secretizing monoclonal antibodies against rickettsia conorii
ATE92102T1 (de) Genfragmente, die die variable region eines anti- hiv-antikoerpers codieren, von diesen exprimierte chimaere anti-hiv-antikoerper und verfahren zu deren herstellung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 549581

Country of ref document: ES